Published 5 January 2009, doi:10.1136/bmj.a3178
Cite this as: BMJ 2009;338:a3178

Views & Reviews

It sticks in our throats too

Sean Ainsworth, consultant neonatologist, Forth Park Hospital, Kirkcaldy, Fife , Wendy Jones, prescribing support pharmacist, The Breastfeeding Network, Paisley, Renfrewshire

Correspondence to: S Ainsworth sean.ainsworth@nhs.net

The first 150 words of the full text of this article appear below.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) claims to "enhance and safeguard the health of the public by ensuring that medicines and medical devices work, and are acceptably safe."1 Why is it then that instead of changing advice in the summary of product characteristics for the most effective treatment for oral thrush2 to minimise the potential for harm they instead make it an "off licence" product for the very group most in need of it?3

Miconazole oral gel was launched in 1978 and has been used to treat countless infants with symptoms of oral thrush. After more than 30 years of unchanged use the manufacturer, Janssen-Cilag, with the support of the MHRA, chose to change its licensed use in May 2008 such that it is no longer recommended in infants aged under 4 months.3 You might assume that this action was taken in the light of serious adverse . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ